Company’s focus on advancing first-in-class oral degraders with biologics-like activity to address areas of significant patient need and market potential STAT6 oral degrader KT-621, with ...

IRF5 program strengthens Kymera’s oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug IRF5, a ...